

30 May 2025

Presentation from AGM and

Clarification on Nano-Collagen Licensing Agreement

Holista Colltech Limited (ASX: HCT) (“Holista” or the “Company”) advises that the attached presentation was delivered by the Interim CEO, Leong Man Loong at the Company’s Annual General Meeting held on 29 May 2025.

Further to the announcement dated 27 May 2025 titled “*Update on Collagen Business*”, the Company wishes to clarify its current position regarding the proposed licensing arrangement with Regenerex for the marketing of Nano-Collagen.

Holista confirms that it has not yet entered into a binding licensing agreement with Regenerex. Discussions are ongoing, and the Company is working towards finalising an agreement within the next 60 days.

The Company cautions investors that there is no guarantee that a binding agreement will be executed, and accordingly, no investment decision should be made based on any assumption that such an agreement will proceed.

This announcement has been authorised for release by the Board of Directors.

-- ENDS --

About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions, listed on the Australian Securities Exchange. The Company operates across four core business divisions: Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control Solutions.

Holista’s portfolio includes market-leading nutritional supplements, patented low-GI food ingredients adopted by global food manufacturers, premium disease-free ovine collagen, and all-natural, non-toxic sanitizers for consumer and industrial use. These offerings reflect Holista’s commitment to combining the best of nature and science to support healthier modern lifestyles.


With a strong track record of research, development, and commercialization, Holista has pioneered several proprietary technologies in the global health and wellness sector. The Company remains dedicated to delivering sustainable, science-backed solutions that enrich lives and promote better living worldwide.

HOLISTA
COLLTECH

FY2024 Annual General Meeting (AGM)

Perth, Australia

29 May 2025



Disclaimer



This document has been prepared by Holista Colltech Limited and comprises written material/slides for a presentation concerning Holista Colltech Limited and its subsidiaries.

The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase, or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision.

Certain statements in this presentation are forward looking statements. You can identify these statements by the fact that they use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward looking statements speak only as at the date of this presentation. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.


No representation, warranty or assurance (express or implied) is given or made by Holista Colltech Limited that the forward looking statements contained in this presentation are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Holista Colltech Limited and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss of damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Subject to any continuing obligation under applicable law or any relevant listing rules of the ASX, Holista Colltech Limited disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change of events, conditions, or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Holista Colltech Limited since the date of this presentation.

Agenda



- Recent Corporate Developments
- FY2024 Financial Highlights
- Update of Collagen Business
- Forward Strategy & Outlook
- AGM Resolutions



Recent Corporate Developments



Second & final payment of \$900K to settle ASIC penalty completed on 12 March 2025 (fulfilled all outstanding obligations as directed by Federal Court)



Funds from 2 Converting Notes – \$1.53M received in March 2025 (convertible at \$0.0315 by 30 June 2025)




Mr Leong Man Loong (ED) appointed as Interim CEO w.e.f. 3 Jan 2025



Recent Changes to the Board – KK Lai as Independent Chairman, 2 Non-Independent Directors (Leong Man Loong and Greg Pilant) and 2 IDs – Rob Gemelli and Sam Yee

2024 Financial Highlights



Revenue: \$5.6M (decrease from \$5.9M in FY2023 due to market challenges/ product mix)

Net Loss After Tax: -\$87k, significantly improved from -\$4.9M in FY2023. Recovered debt of \$560K and \$534K from trade receivables; reversal of provisions related to legal settlements and costs of reinstatement of Collie facility


Balance Sheet

Total Assets: \$3.34M vs \$3.35M in FY2023.

Total Liabilities: \$6.71M vs \$6.74M in FY2023

Shareholders' Equity: Negative \$3.37M, reflecting accumulated losses (Issued 2 converting notes in March 2025 to raise \$1.53M)

Chronology of Recent Developments



Business Segments



Dietary Supplements

- Malaysian dietary supplements market valued at USD 644.88M in 2023, projected to grow at CAGR of 5.2%.
- Challenges include evolving regulations & counterfeit products

Infection Control & Agriculture

- In FY2025, this division expanded to include Agriculture; currently jointly developing a probiotics formulation for poultry

Food Ingredients

- Major products are formulas for low-sugar and flour mix to lower Glycemic Index
- Rising costs of raw materials due to inflation and regulatory matters (compliance with international food safety standards and halal certification)

Collagen Segment – Update



01

Production at Collie ceased after expiry of lease; reinstatement completed on 1 Nov 2024; Applied to Collie Futures Small Grants Program for \$100K to support a new facility to be set up in 2026

02

Will be scalable and more cost-efficient

03

New facility will adopt modular, asset-light approach using sea containers customised for equipment, production and storage

04

Sufficient buffer stock to meet business needs until new facility is set up

Nano-Collagen Related Developments



Targeting medical applications, e.g. wound healing & organ printing – move up value chain beyond collagen for cosmetics use

Partnered with Akrivis of India to develop nano-collagen; Filed patent for nano-collagen (awaiting approval)

Also developing with Akrivis product for nano-collagen to be applied to skin (transdermal)

Holista & Ultraverse secured grant of \$163K from NanoMalaysia to develop & patent halal-certified ovine nano-collagen

Proposal For Nano-Collagen & Exosome Facility in Sarawak



Holista has held several rounds of discussion with government of Sarawak state in Malaysia to establish dedicated production facility in biotech hub in Kuching

Holista intends to form JV and avail itself to funding, regulatory and other support from Sarawak state

Facility will produce halal nano-collagen using ovine collagen stock from Collie

Will also produce exosomes (nano-sized extra-cellular vesicles that can offer advanced applications in drug delivery, liquid biopsies and for regenerative medicine)

Licensing Agreement with U.S. Company Specialising in Wound Healing



- Regenerex has evaluated nano-collagen samples; believes it can provide major benefits for wound healing
- It is commencing clinical studies to use nano-collagen for wound healing, and filing regulatory approvals with the U.S. FDA
- Holista is completing licensing agreement for Regenerex to market nano-collagen in international markets
- Regenerex is listed on U.S. OTC Market; major shareholder is Mr. Gregory Pilant who was appointed as Non-Executive, Non-Independent Director on 26 March 2025



Thank You

For further information, please contact:

Corporate Matters: investors@holistaco.com

General Enquiries: enquiries@holistaco.com

